Literature DB >> 25772676

Alternative delivery of a thermostable inactivated polio vaccine.

Heleen Kraan1, Ivo Ploemen2, Gijsbert van de Wijdeven3, Ivo Que4, Clemens Löwik4, Gideon Kersten5, Jean-Pierre Amorij2.   

Abstract

In the near future oral polio vaccine (OPV) will be replaced by inactivated polio vaccine (IPV) as part of the eradication program of polio. For that reason, there is a need for substantial amount of safe and more affordable IPV for low-income countries. Bioneedles, which are biodegradable mini-implants, have the potential to deliver vaccines outside the cold-chain and administer them without the use of needles and syringes. In the current study, Bioneedles were filled with IPV, subsequently lyophilized, and antigenic recoveries were determined both directly after IPV-Bioneedle preparation as well as after elevated stability testing. Further, we assessed the immunogenicity of IPV-Bioneedles in rats and the residence time at the site of administration. Trivalent IPV was formulated in Bioneedles with recoveries of 101±10%, 113±18%, and 92±15%, respectively for serotypes 1, 2 and 3. IPV in Bioneedles is more resistant to elevated temperatures than liquid IPV: liquid IPV retained less than half of its antigenicity after 1 day at 45°C and IPV in Bioneedles showed remaining recoveries of 80±10%, 85±4% and 63±4% for the three serotypes. In vivo imaging revealed that IPV administered via Bioneedles as well as subcutaneously injected liquid IPV showed a retention time of 3 days at the site of administration. Finally, an immunogenicity study showed that IPV-filled Bioneedles are able to induce virus-neutralizing antibody titers similar to those obtained by liquid intramuscular injection when administered in a booster regime. The addition of LPS-derivate PagL in IPV-filled Bioneedles did not increase immunogenicity compared to IPV-Bioneedles without adjuvant. The current study demonstrates the pre-clinical proof of concept of IPV-filled Bioneedles as a syringe-free alternative delivery system. Further pre-clinical and clinical studies will be required to assess the feasibility whether IPV-Bioneedles show sufficient safety and efficacy, and may contribute to the efforts to eradicate and prevent polio in the future.
Copyright © 2015 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Adjuvant; Biodistribution; Bioneedles; Needle free; Vaccine delivery

Mesh:

Substances:

Year:  2015        PMID: 25772676     DOI: 10.1016/j.vaccine.2015.03.011

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

1.  Thin silk fibroin films as a dried format for temperature stabilization of inactivated polio vaccine.

Authors:  Jordan A Stinson; Carter R Palmer; David P Miller; Adrian B Li; Kandice Lightner; Heather Jost; William C Weldon; M Steven Oberste; Jonathan A Kluge; Kathryn M Kosuda
Journal:  Vaccine       Date:  2020-01-17       Impact factor: 3.641

2.  Determination of Depth-Dependent Intradermal Immunogenicity of Adjuvanted Inactivated Polio Vaccine Delivered by Microinjections via Hollow Microneedles.

Authors:  Pim Schipper; Koen van der Maaden; Stefan Romeijn; Cees Oomens; Gideon Kersten; Wim Jiskoot; Joke Bouwstra
Journal:  Pharm Res       Date:  2016-06-17       Impact factor: 4.200

3.  Thermostabilization of inactivated polio vaccine in PLGA-based microspheres for pulsatile release.

Authors:  Stephany Y Tzeng; Rohiverth Guarecuco; Kevin J McHugh; Sviatlana Rose; Evan M Rosenberg; Yingying Zeng; Robert Langer; Ana Jaklenec
Journal:  J Control Release       Date:  2016-05-11       Impact factor: 9.776

4.  Incompatibility of lyophilized inactivated polio vaccine with liquid pentavalent whole-cell-pertussis-containing vaccine.

Authors:  Heleen Kraan; Rimko Ten Have; Larissa van der Maas; Gideon Kersten; Jean-Pierre Amorij
Journal:  Vaccine       Date:  2016-07-26       Impact factor: 3.641

5.  Development of Stabilizing Formulations of a Trivalent Inactivated Poliovirus Vaccine in a Dried State for Delivery in the Nanopatch™ Microprojection Array.

Authors:  Ying Wan; John M Hickey; Christopher Bird; Katey Witham; Paul Fahey; Angus Forster; Sangeeta B Joshi; David B Volkin
Journal:  J Pharm Sci       Date:  2018-02-06       Impact factor: 3.534

6.  Stabilized single-injection inactivated polio vaccine elicits a strong neutralizing immune response.

Authors:  Stephany Y Tzeng; Kevin J McHugh; Adam M Behrens; Sviatlana Rose; James L Sugarman; Shiran Ferber; Robert Langer; Ana Jaklenec
Journal:  Proc Natl Acad Sci U S A       Date:  2018-05-21       Impact factor: 11.205

7.  High-density microprojection array delivery to rat skin of low doses of trivalent inactivated poliovirus vaccine elicits potent neutralising antibody responses.

Authors:  David A Muller; Germain J P Fernando; Nick S Owens; Christiana Agyei-Yeboah; Jonathan C J Wei; Alexandra C I Depelsenaire; Angus Forster; Paul Fahey; William C Weldon; M Steven Oberste; Paul R Young; Mark A F Kendall
Journal:  Sci Rep       Date:  2017-10-03       Impact factor: 4.379

8.  Development of Thermostable Lyophilized Sabin Inactivated Poliovirus Vaccine.

Authors:  Woo-Jin Shin; Daiki Hara; Francisca Gbormittah; Hana Chang; Byeong S Chang; Jae U Jung
Journal:  MBio       Date:  2018-11-27       Impact factor: 7.867

Review 9.  How the use of vaccines outside the cold chain or in controlled temperature chain contributes to improving immunization coverage in low- and middle-income countries (LMICs): A scoping review of the literature.

Authors:  Ibrahim K Dadari; Janice C Zgibor
Journal:  J Glob Health       Date:  2021-01-31       Impact factor: 4.413

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.